Blab AI
Arintra Secures $25 Million Series B to Expand AI-Driven Medical Coding Platform
On August 26, 2026, Arintra announced a $25 million Series B round that lifted its total capital to $51 million. The San Francisco‑based startup, which automates medical coding across 23 clinical specialties, now has a fresh injection of capital to accelerate its AI‑powered revenue‑cycle solutions.
The round was led by Define Ventures and saw participation from a mix of strategic and existing backers. Peak XV Partners, the Yale New Haven Health Center for Health Care Innovation, Endeavor Health Ventures, Y Combinator, Counterpart Ventures, Ten13, and Spider Capital all contributed. Endeavor Health, a Chicago‑area health‑tech firm that adopted Arintra’s platform during its Series A, joined the new funding.
Arintra’s platform centers on an agentic AI model that autonomously codes patient charts and extends its intelligence to clinical documentation improvement (CDI), denial appeals, payer insights, and diagnostic‑related group (DRG) validation. It currently serves specialties such as emergency department, hospitalist, radiology, primary care, internal/family medicine, and urgent care.
Early adopters—including UC Davis Health, Mercyhealth, Meritus Health, Rochester Regional Health, Reid Health, and Mercy Medical Center—have reported tangible gains. UC Davis Health’s executive director of mid‑revenue cycle, Tami McMasters Gomez, noted that the platform’s audit trail and explainable AI features let coding professionals validate decisions within the electronic health record. She added that her team could audit results roughly 50 % faster than manual processes while preserving coding quality and compliance.
Arintra claims its solution processes more than $5 billion in annual claim value for enterprises that collectively generate over $50 billion in net patient revenue. The company cites a 5.1 % lift in compliant revenue capture, a 32 % cut in coding costs, and a 43 % drop in coding‑related denials. The platform is available through the Epic Toolbox and the athenahealth Marketplace.
With the new capital, Arintra plans to broaden its reach to additional enterprise health systems, deepen clinical and specialty coverage, and extend the platform into new areas of the revenue cycle. The funding will also support scaling its autonomous coding capabilities and enhancing AI‑driven revenue assurance services.
The timing of the Series B aligns with a broader industry push to automate revenue‑cycle functions amid workforce shortages and a drive for reimbursement accuracy. Market reports indicate steady growth in AI‑enabled coding and revenue‑cycle solutions over recent years.
Arintra’s round signals sustained investor confidence in autonomous coding platforms and underscores the strategic value of integrating such technology with wider revenue‑cycle operations. Upcoming milestones include deeper integration with major electronic health record vendors and the launch of additional AI modules for payer analytics and denial management.
As the platform scales, health systems will assess its impact on coding workflows, compliance, and cost structures. The company’s claims of faster audit cycles and lower denial rates will be closely monitored by adopters and analysts alike.
Today, Arintra stands with $25 million in Series B funding, a growing customer base across U.S. health systems, and a roadmap that calls for expanded product offerings, broader market reach, and new AI modules to support denial appeals and payer insights.
The round was led by Define Ventures and saw participation from a mix of strategic and existing backers. Peak XV Partners, the Yale New Haven Health Center for Health Care Innovation, Endeavor Health Ventures, Y Combinator, Counterpart Ventures, Ten13, and Spider Capital all contributed. Endeavor Health, a Chicago‑area health‑tech firm that adopted Arintra’s platform during its Series A, joined the new funding.
Arintra’s platform centers on an agentic AI model that autonomously codes patient charts and extends its intelligence to clinical documentation improvement (CDI), denial appeals, payer insights, and diagnostic‑related group (DRG) validation. It currently serves specialties such as emergency department, hospitalist, radiology, primary care, internal/family medicine, and urgent care.
Early adopters—including UC Davis Health, Mercyhealth, Meritus Health, Rochester Regional Health, Reid Health, and Mercy Medical Center—have reported tangible gains. UC Davis Health’s executive director of mid‑revenue cycle, Tami McMasters Gomez, noted that the platform’s audit trail and explainable AI features let coding professionals validate decisions within the electronic health record. She added that her team could audit results roughly 50 % faster than manual processes while preserving coding quality and compliance.
Arintra claims its solution processes more than $5 billion in annual claim value for enterprises that collectively generate over $50 billion in net patient revenue. The company cites a 5.1 % lift in compliant revenue capture, a 32 % cut in coding costs, and a 43 % drop in coding‑related denials. The platform is available through the Epic Toolbox and the athenahealth Marketplace.
With the new capital, Arintra plans to broaden its reach to additional enterprise health systems, deepen clinical and specialty coverage, and extend the platform into new areas of the revenue cycle. The funding will also support scaling its autonomous coding capabilities and enhancing AI‑driven revenue assurance services.
The timing of the Series B aligns with a broader industry push to automate revenue‑cycle functions amid workforce shortages and a drive for reimbursement accuracy. Market reports indicate steady growth in AI‑enabled coding and revenue‑cycle solutions over recent years.
Arintra’s round signals sustained investor confidence in autonomous coding platforms and underscores the strategic value of integrating such technology with wider revenue‑cycle operations. Upcoming milestones include deeper integration with major electronic health record vendors and the launch of additional AI modules for payer analytics and denial management.
As the platform scales, health systems will assess its impact on coding workflows, compliance, and cost structures. The company’s claims of faster audit cycles and lower denial rates will be closely monitored by adopters and analysts alike.
Today, Arintra stands with $25 million in Series B funding, a growing customer base across U.S. health systems, and a roadmap that calls for expanded product offerings, broader market reach, and new AI modules to support denial appeals and payer insights.
